Recent Updates
Recently added Catalysts

Axsome Therapeutics, Inc.

AXSMFDA catalysts, PDUFA dates & pipeline intelligence
$135.95
▼ -1.06 · -0.77%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full AXSM financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $123.0052W HIGH $260.19
Volume
518.79 K
Value Traded
70.51 M
Short % Float
7.35%
Days to Cover
3.4
-8.91%Week
-12.75%1 Month
-37.69%3 Month
-41.05%6 Month
+320.77%5 Year
+2,521.89%All Time

Cash Data

Unlock AXSM cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
7.15 B
EPS (TTM)
-2.99
P/E Ratio
-
Ent. Value
7.03 B
Total Shares
52.60 M
Float Shares
44.37 M
Insiders
15.65%
Institutions
75.15%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 topline data readout
Solriamfetol
Binge eating disorder
Phase 3Small MoleculesPsychiatry
Unlock every AXSM catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

AXSM Catalyst Timeline

Dated clinical, regulatory and corporate events for Axsome Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Axsome Therapeutics, Inc.

887Total events
11Upcoming
228Tier-1 (high impact)
2015 to 2040Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
SolriamfetolApproved
T1Topline Readout
Subscribe to view catalyst details
SolriamfetolApproved

Event history 50

●Quarterly UpdateCorporate
Axsome reports third quarter 2026 financial results and business update
●Poster PresentationPresentation
Shared Goals survey results presented at Psych Congress 2026
agitation associated with dementia due to Alzheimer's diseasesource ↗
●Poster PresentationAXS-05ApprovedPresentation
Poster 102: Effects of Dextromethorphan-Bupropion (45mg/105mg) in Participants with Major Depressive Disorder and Anxious Distress
Major depressive disorder with anxious distresssource ↗
●Poster PresentationSolriamfetolApprovedPresentation
Poster 156: Solriamfetol for Excessive Daytime Sleepiness in Narcolepsy and OSA: Post-hoc Multi-dimensional Composite Endpoint Analysis of Phase 3 Trials
Excessive daytime sleepiness in narcolepsy and obstructive sleep apneasource ↗
●Poster PresentationAXS-12FiledPresentation
Poster 154: Cognitive and Functional Outcomes from the Phase 3 Open-Label Extension and Randomized-Withdrawal ENCORE Trial of AXS-12 in Narcolepsy with Cataplexy
Narcolepsy with cataplexysource ↗
▲First Patient DosedAXS-05ApprovedTrial
First patient dosed in SUMMIT Phase 3 trial of AXS-05 for smoking cessation
smoking cessationsource ↗
●Quarterly UpdateCorporate
Second quarter 2026 financial results reported
▲FDA Filing AcceptedAXS-12FiledRegulatory Filing
NDA submission for AXS-12 accepted by FDA
cataplexy in narcolepsysource ↗
●Trial InitiationAXS-05ApprovedTrial
Axsome initiated Phase 3 SUMMIT trial of AXS-05 in smoking cessation
smoking cessationsource ↗
▲FDA Filing AcceptedAXS-12FiledRegulatory Filing
FDA accepts NDA for AXS-12 for cataplexy in narcolepsy
cataplexy in narcolepsysource ↗
Unlock the full AXSM catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How AXSM actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-09-18AXS-12 Phase 3 data presentation Phase 3
Unlock 14 more AXSM historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 7%
Small Cap
(rank 52 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
Auvelity
Sunosi
Symbravo
Showing 15 of 17 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Solriamfetol Small MoleculesNCT06878976Binge-Eating DisorderPhase 3 ENROLLING BY_INVITATION 686Dec 1, 2027
Solriamfetol Small MoleculesNCT07484217Major Depressive Disorder With Excessive Daytime Sleepiness SymptomsPhase 3 RECRUITING 508Dec 1, 2028
Solriamfetol Small MoleculesMarketedNCT06568367Excessive SleepinessApproved RECRUITING 520Dec 1, 2026
AXS-14 Small MoleculesNCT07637162FibromyalgiaPhase 3 ENROLLING BY_INVITATION 920May 1, 2028
AXS-12 Small MoleculesCompletedNCT03881852NarcolepsyNDA/BLA COMPLETED 179Nov 27, 2019
Solriamfetol Small MoleculesNot countedNCT06360419Major Depressive DisorderPhase 3 COMPLETED 346Mar 26, 2025
Solriamfetol Small MoleculesNCT05972044ADHDPhase 3 COMPLETED 1,752Mar 14, 2025
Solriamfetol Small MoleculesMarketedNCT05008341NarcolepsyApproved COMPLETED 6Apr 15, 2022
AXS-05 Small MoleculesNot countedNCT03595579Major Depressive DisorderPhase 3 COMPLETED 973Jan 7, 2019
AXS-05 Small MoleculesNot countedNCT04019704DepressionPhase 3 COMPLETED 327Dec 5, 2019
AXS-05 Small MoleculesNot countedNCT02741791Treatment Resistant Major Depressive DisorderPhase 3 COMPLETED 312Mar 20, 2020
AXS-05 Small MoleculesMarketedNCT04797715Agitation in Patients With Dementia of the Alzheimer's TypeApproved COMPLETED 1,408Nov 21, 2022
AXS-05 Small MoleculesNCT03471767Smoking CessationPhase 3 COMPLETED 763Mar 31, 2019
AXS-05 Small MoleculesNot countedNCT04608396Treatment Resistant DepressionPhase 2 COMPLETED 44Jul 30, 2021
AXS-07 Small MoleculesMarketedNCT03896009MigraineApproved COMPLETED 2,702Dec 10, 2019
Unlock the AXSM pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every AXSM program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Dextromethorphan-Bupropion
Breakthrough
Major Depressive Disorder2026-09-17Anti-Anhedonic Effects of Dextromethorphan-Bupropion Mediate Improvements in Functioning and Quality of Life in Major Depressive DisorderRead MoreAxsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026Read More
Scroll for more · summaries link to the source press release
Unlock every AXSM trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock AXSM insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Jacobson Mark L.Officer (Chief Operating Officer)Option 10,000 10,000 held$12.95 09/03/2026
Unlock the full AXSM insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Deep Track Capital, LP 2.4 % (-4 %) 147.51 M 800.00 K 14.29% ( 100.00 K)
Unlock every fund holding AXSM
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in AXSM
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see AXSM ownership
Insider and institutional ownership, quarter by quarter.

AXSM Short Interest

Shares sold short, counted twice a month.

7.35%
Short % of Float
of tradable shares sold short
3.3M
Shares Sold Short
+4.9% vs prior count
3.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
975.2K
Avg Daily Volume
the average used for days to cover
Unlock AXSM short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock AXSM option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live AXSM option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock AXSM options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How AXSM ranks across every disease it competes in

Competitive Position is a premium feature
See how AXSM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

AXSM News

AXSM
Nov 3, 2026
AXSMConferences/Events

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics announced its participation in several investor conferences throughout November 2026. Notable events include the Guggenheim Healthcare Innovation Conference and the UBS Global Biopharma Conference. Live webcasts of these presentations will be accessible on the company's website, providing investors with insights into its CNS treatment advancements.

Read more →
AXSM
Nov 2, 2026
AXSMGeneral
▼ -5.8%on this newsshared move

Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Axsome Therapeutics reported a 52% increase in total net product revenue for Q3 2026, reaching $259.7 million. AUVELITY sales contributed significantly, growing by 53% year-over-year. The company also initiated the SUMMIT Phase 3 trial for AXS-05 aimed at smoking cessation. Despite the growth, Axsome reported a net loss of $12.9 million.

Read more →
AXSM
Oct 7, 2026
AXSMConferences/Events

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

Axsome Therapeutics will report its third quarter 2026 financial results on November 2, 2026. A conference call will follow at 8:00 a.m. ET to discuss these results and provide a business update. The company focuses on innovative treatments for CNS disorders and has several FDA-approved products.

Read more →
AXSM
Sep 21, 2026
AXSMGeneral

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

Axsome Therapeutics presented results from the Shared Goals survey at Psych Congress 2026, highlighting the significant impact of agitation in Alzheimer's disease on patients and caregivers. The survey revealed that 97% of caregivers noted a negative effect on their loved ones' quality of life, with many wishing they had recognized symptoms earlier. Caregivers expressed a desire for better resources and support in managing agitation symptoms.

Read more →
AXSM
Sep 17, 2026
AXSMConferences/Events

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

Axsome Therapeutics presented ten posters at Psych Congress 2026, highlighting new data on major depressive disorder and Alzheimer's disease agitation. The presentations included real-world treatment patterns and clinical outcomes, showcasing the company's advancements in CNS disorder treatments. This event underscores Axsome's commitment to addressing critical gaps in psychiatric and neurological care.

Read more →
AXSM
Aug 31, 2026
AXSMPhases

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

Axsome Therapeutics has initiated the SUMMIT Phase 3 trial for AXS-05, targeting smoking cessation. This trial will evaluate the efficacy and safety of AXS-05 compared to bupropion and placebo over a 12-week period. Smoking cessation remains a critical health issue, with millions of adults seeking effective treatments.

Read more →
AXSM
Aug 10, 2026
AXSMGeneral

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Axsome Therapeutics reported a strong financial performance for Q2 2026, with total net product revenue reaching $218.4 million, a 46% increase year-over-year. The company highlighted robust sales growth for AUVELITY and SUNOSI, alongside the successful launch of AUVELITY for Alzheimer's agitation. Additionally, Axsome initiated Phase 3 trials for solriamfetol in ADHD and received FDA acceptance for its NDA submission for AXS-12 targeting narcolepsy. Despite a net loss of $51.3 million, the company remains optimistic about its commercial prospects.

Read more →
AXSM
Jul 15, 2026
AXSMFDA Updates

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Axsome Therapeutics announced the FDA's acceptance of its New Drug Application for AXS-12, aimed at treating cataplexy in narcolepsy. The FDA has set a target action date of May 1, 2027, and does not plan to hold an advisory committee meeting regarding the application. AXS-12 is a norepinephrine reuptake inhibitor designed to help maintain muscle tone during wakefulness.

Read more →
AXSM
Jul 14, 2026
AXSMConferences/Events

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

Axsome Therapeutics will announce its second quarter 2026 financial results on August 10, 2026, prior to the U.S. market opening. Following the report, management will host a conference call to discuss the results and provide a business update. The call will be accessible via phone and webcast, with a replay available for 30 days.

Read more →
AXSM
Jul 7, 2026
AXSMPhases

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

Axsome Therapeutics has commenced the FOCUS-2 Phase 3 trial for solriamfetol, targeting children aged 6 to under 12 with ADHD. This trial follows the FOCUS-3 trial for adolescents and aims to evaluate the drug's efficacy and safety. Approximately 468 children will participate, with results expected to contribute to ADHD treatment advancements.

Read more →
AXSM
Jun 26, 2026
AXSMPhases

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

Axsome Therapeutics has commenced the FOCUS-3 Phase 3 trial for solriamfetol, targeting adolescents aged 12 to under 18 with ADHD. This randomized, double-blind study will evaluate the drug's efficacy and safety over six weeks, with 468 participants receiving either solriamfetol or a placebo. The primary measure will be the change in ADHD symptoms as assessed by the ADHD Rating Scale.

Read more →
AXSM
Jun 18, 2026
AXSMGeneral

Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month

Axsome Therapeutics is emphasizing the importance of brain health during Alzheimer's & Brain Awareness Month. The company is collaborating with patients, caregivers, and advocacy organizations to promote awareness and provide resources. They will participate in over 30 events aimed at ending Alzheimer's and will illuminate their headquarters in purple to support the cause.

Read more →
AXSM
Jun 15, 2026
AXSMConferences/Events

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026

Axsome Therapeutics presented new data on its sleep medicine portfolio at SLEEP 2026, highlighting AXS-12 and solriamfetol. The presentations included findings from Phase 3 trials and analyses related to narcolepsy and excessive daytime sleepiness. The event showcased the company's commitment to advancing treatments for central nervous system disorders.

Read more →
AXSM
Jun 4, 2026
AXSMConferences/Events

Axsome Therapeutics Presents New SYMBRAVO Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

Axsome Therapeutics presented new data on SYMBRAVO for migraine treatment at the American Headache Society meeting. The company shared results from the Phase 3 MOMENTUM and MOVEMENT trials. Presentations also included a network meta-analysis comparing SYMBRAVO to gepants. These updates cover efficacy and safety endpoints for the acute treatment of migraine.

Read more →
AXSM
Jun 3, 2026
AXSMFDA Updates
▲ +5.1%on this newsshared move

Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

Axsome Therapeutics has successfully settled all patent litigation concerning its product SUNOSI (solriamfetol). The settlement permits five companies to sell generic versions of SUNOSI starting in 2040, subject to FDA approval. This resolution eliminates any remaining patent disputes related to SUNOSI, allowing Axsome to focus on its broader business objectives.

Read more →
AXSM
Jun 1, 2026
AXSMGeneral

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

Axsome Therapeutics is enhancing its commitment to the migraine community by supporting educational initiatives during Migraine and Headache Awareness Month. The company is backing the Headache in the City campaign and illuminating its headquarters in purple to raise awareness. This effort aims to reduce stigma and improve understanding of migraine's impact on millions.

Read more →
AXSM
May 26, 2026
AXSMConferences/Events

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

Axsome Therapeutics has announced new data presentations on AUVELITY® for major depressive disorder at the ASCP 2026 Annual Meeting. The presentations will cover various aspects of the treatment, including its effects and real-world clinical outcomes. The event is set to take place from May 26-29 in Miami, FL, showcasing advancements in CNS disorder treatments.

Read more →
AXSM
May 7, 2026
AXSMGeneral

Axsome Therapeutics Recognizes Mental Health Month

Axsome Therapeutics is recognizing Mental Health Month by supporting initiatives aimed at improving mental health awareness and providing resources for individuals affected by mental health conditions. The company emphasizes the importance of community support and highlights various organizations that offer educational tools and assistance. This year's theme, 'More Good Days, Together,' focuses on fostering hope and recovery for those impacted by mental illness.

Read more →

About Axsome Therapeutics, Inc.

New York, NY 925 employees axsome.com
HeadquartersONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK, NY, 10007
Founded2012
BIOPHARMAWATCH ELITE
Trade the next AXSM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime